Rationale for the development of a differentiated Trop2 ADC

Trodelvy (sacituzumab govitecan-hziy) - Everest Medicines, Gilead

datopotamab deruxtecan (DS-1062a) - Daiichi Sankyo, AstraZeneca

Trop2 PH1 ADC - Peak Bio

https://www.abstractsonline.com/pp8/#!/10828/presentation/8682

Satyajit K. Mitra1; William Monteith1; Mary Do2; Greg Tuffy3; Scott Savage4; Jeffrey Kang2; Mastewal Abuhay1; Teodora Losic2; Sanjeevani Ghone1; William E. Haskins1; Vasu Jammalamadaka5; Sanjeev Satyal6

Mar 14, 2023